116057-57-9

Farnesyl pyrophosphate is an intermediate in the HMG-CoA reductase pathway and used in the biosynthesis of terpenes, terpenoids, and sterols. It also serves as a donor in post-translational isoprenylation of proteins. FPP has been identified as an antagonist of P2Y₁₂ receptors (IC₅₀ = 45 μM), attenuating platelet aggregation. It has also been shown to regulate adipocyte function as an endogenous PPARγ agonist. Additionally, because of a flexible hydrocarbon chain that enables different conformations, FPP is a promiscuous ligand for a subset of nuclear receptors.

Pale Yellow Low Melting Solid

Isoprenoid from the intracellular mevalonate pathway used for prenylation of several low molecular mass G proteins, including Ras.

Isoprenoid from the intracellular mevalonate pathway, Farnesyl Pyrophosphate Triammonium Salt can be used for prenylation of several low molecular mass G proteins, including Ras.

[1] MCTAGGART S J. Isoprenylated proteins.[J]. Cellular and Molecular Life Sciences, 2006, 63 3: 255-267. DOI: 10.1007/s00018-005-5298-6
[2] CARL H?GBERG. Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y?? receptor-mediated platelet aggregation.[J]. Thrombosis and haemostasis, 2012, 108 1: 119-132. DOI: 10.1160/th11-10-0749
[3] TSUYOSHI GOTO. Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARγ agonist.[J]. Biochemical Journal, 2011: 111-119. DOI: 10.1042/bj20101939
[4] RITU GOYANKA. Nuclear receptor engineering based on novel structure activity relationships revealed by farnesyl pyrophosphate.[J]. Protein Engineering Design & Selection, 2010, 23 11: 809-815. DOI: 10.1093/protein/gzq056